Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD
Positive high-level results from the Phase III OBERON and TITANIA trials in patients with chronic ob...
Publisher
UK
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
Positive high-level results from the Phase III OBERON and TITANIA trials in patients with chronic ob...
Source route
Continue on astrazeneca.com
Leave the platform to read the original full article on the publisher site.
Source: AstraZeneca News
Scope: Industry
Related coverage
More related coverage
Press releaseMar 27, 2026Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation- Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases - Lead asset Exl-111 builds on proven IgE biology with a differentiated…
- Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven...
2026 03 27 12 00 00 3263711
Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU appr...
20260327 Whc Reg
Gedeon Richter Investors Announcements Richter receives European Commission approval for FYLREVY® (E...
Mar.26.2026R & DOno Pharma Submits an Application for Approval of Ripretinib (DCC-2618) in Patients with Advanced Gastrointestinal Stromal Tumor in Japan
Application submitted for manufacturing and marketing approval of ripretinib in Japan for the indica...